RecruitingNot ApplicableNCT04452162

Physiologic MR Imaging of Salivary Gland Tumors

Physiologic MR Imaging in Distinguishing Benign From Malignant Salivary Gland Tumors

Sponsor

Abramson Cancer Center at Penn Medicine

Enrollment

30 participants

Start Date

Aug 25, 2020

Study Type

INTERVENTIONAL

Conditions

Salivary Gland Tumor

Summary

The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a specialized type of MRI to better characterize tumors in the salivary glands (glands that produce saliva, located near the jaw and ears), which are often difficult to distinguish as benign or cancerous without surgery. **You may be eligible if...** - You have a salivary gland growth (lesion) of at least 1 cm - You have not had any prior treatment for this salivary gland lesion - You are able to safely undergo an MRI scan **You may NOT be eligible if...** - You have a history of any prior cancer other than salivary gland tumors - You have any contraindication to MRI (e.g., metal implants, pacemaker) - You have known kidney disease (which can affect use of MRI contrast dye) - You have previously received radiation to the head and neck - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTMRI

You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.

Locations(1)

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04452162

Related Trials

Immune Biomarker Study for Salivary Gland Carcinoma

NCT060472362 locations

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

NCT049698359 locations